Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma

Published:2021-11 Issue: Volume: Page:
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Dong Olivia M.,Poonnen Pradeep J.,Winski David,Reed Shelby D.,Vashistha Vishal,Bates Jill,Kelley Michael J.,Voora Deepak

Funder

AstraZeneca

National Human Genome Research Institute

Genentech

Bristol-Myers Squibb

Novartis

National Institutes of Health

International Business Machines Corporation

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference48 articles.

1. Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with first-line therapies for Medicare patients 65 years and older with advanced non-small-cell lung cancer: a retrospective study;Bittoni;Clin Lung Cancer,2018

2. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets;Cohen;Oncologist,2003

3. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis;Wao;Syst Rev,2013

4. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature;Marino;Chest,1994

5. Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations;König;Cancers (Basel),2021

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world clinical and economic outcomes for patients with advanced non–small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy;Journal of Managed Care & Specialty Pharmacy;2024-07

2. Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non–small cell lung cancer;Journal of Managed Care & Specialty Pharmacy;2024-07

3. Value of next generation sequencing (NGS) testing in advanced cancer patients;Journal of Medical Economics;2024-04-02

4. Cost-Effectiveness and the Economics of Genomic Testing and Molecularly Matched Therapies;Surgical Oncology Clinics of North America;2024-04

5. Early prediction of response to palliative chemotherapy in patients with stage-IV gastric and esophageal cancer;BMC Cancer;2023-09-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3